Welcome to our dedicated page for TANDEM DIABETES CARE SEC filings (Ticker: TNDM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TANDEM DIABETES CARE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TANDEM DIABETES CARE's regulatory disclosures and financial reporting.
Tandem Diabetes Care insider Shannon M. Hansen reported multiple transactions on 08/15/2025 related to restricted stock units (RSUs) and common stock. The filing shows vesting-driven acquisitions: 531, 1,437 and 1,097 RSUs converted into common stock (total underlying 3,065 shares added to direct holdings) and corresponding increases in direct common stock ownership to a reported 7,677 shares of derivative-backed common stock and 19,102 shares of direct common stock at various steps. Several entries show shares withheld to satisfy tax withholding at $10.82 per share; no open-market sales were reported. The securities held indirectly are in the Shannon M. Hansen Trust.
Elizabeth A. Gasser, EVP and Chief Strategy Officer of Tandem Diabetes Care, reported multiple transactions on 08/15/2025 affecting her holdings of TNDM common stock. She acquired 1,503 shares (RSU vesting) and an additional 1,097 shares (RSU vesting), both reported as acquisitions at $0 per share. To satisfy tax withholding on vesting, 805 and 588 shares were withheld and disposed at $10.82 per share; no shares were sold on the open market. She directly beneficially owns 4,509 shares from vested RSUs and 7,677 shares from other RSUs per the table, and indirectly holds 22,949 shares through The Gasser Family Trust, where she is a co-trustee.
John F. Sheridan, President & CEO and director of Tandem Diabetes Care, Inc. (TNDM), reported a non-derivative purchase of 10,000 shares on 08/11/2025. The filing states the trades executed at prices ranging from $10.19 to $10.33, with a weighted average purchase price of $10.2318. Following the reported transaction, the reporting person beneficially owned 106,327 shares.
The Form 4 identifies the filing as by one reporting person and includes an explanatory note that full details of the multiple trades (number of shares per trade and individual prices) will be provided upon request. The form is signed by Rachel Malina as attorney-in-fact for John F. Sheridan.
Diabetes Care Inc EVP & Chief Financial Officer Leigh Vosseller reported an open-market purchase of common stock on August 8, 2025. A trust bearing her name bought 13,720 shares at a weighted average price of $10.8895 per share, through multiple trades between $10.86 and $10.90.
After this transaction, the trust holds 25,580 shares indirectly, while Vosseller also holds 33,798 shares directly. The filing notes that the securities are held by the Leigh A. Vosseller Trust, for which she serves as trustee.
Tandem Diabetes Care (NASDAQ:TNDM) filed a routine Form 4 reporting Chief Technology Officer Rick Carpenter’s latest equity transaction.
On June 16 2025, Carpenter acquired 406 common shares through the vesting of previously granted restricted stock units (RSUs) at a stated price of $0. To cover statutory tax withholding, 207 shares were automatically withheld by the company and disposed of at $20.76 per share. Following the transactions, Carpenter directly owns 21,219 shares of Tandem Diabetes Care common stock.
The filing indicates these transfers were executed under the company’s 2013 Stock Incentive Plan and do not involve open-market purchases or sales. No additional derivative positions were reported beyond the RSU conversion.
SEC Form 4 filed on 06/18/2025 reveals that Tandem Diabetes Care, Inc. (TNDM) director Myoungil Cha acquired 1,749 shares of common stock on 06/16/2025 through the vesting and settlement of previously granted restricted stock units (RSUs) under the company’s 2013 Stock Incentive Plan. The conversion, reported with transaction code “M,” was executed at $0 cost to the insider and involved no open-market purchase or sale.
Following the transaction, Cha’s direct beneficial ownership rose from 11,950 to 13,699 shares. The RSU grant was originally awarded on 06/15/2022 and vests in three equal annual installments; the reported shares represent the second installment, with additional tranches scheduled for future anniversaries, subject to plan terms.
Key takeaways:
- Insider ownership increase: +1,749 shares, signalling continued alignment with shareholder interests.
- Routine equity compensation: Transaction stems from standard RSU vesting, not discretionary market activity.
- No cash proceeds or sales: Neutral impact on near-term share flow and insider liquidity.